Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Brian Godman, Andrew Hill, Steven Simoens, Amanj Kurdi, Jolanta Gulbinovič , Antony Martin, Angela Timoney, Dzintars Gotham, Janet Wale, Tomasz Bochenek , Celia Rothe, Iris Hoxha, Admir Malaj, Christian Hierländer, Robert Sauermann, Wouter Hamelinck, Zornitza Mitkova, Guenka Petrova, Ott Laius, Catherine SermetIrene Langer, Gisbert Selke, John Yfantopoulos, Roberta Joppi, Arianit Jakupi, Elita Poplavska, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, JF Piepenbrink, Vincent de Valk, Carolin Hagen, Anne Marthe Ringerud, Robert Plisko, Magdalene Wladysiuk, Vanda Marković-Peković, Nataša Grubiša, Ileana Mardare, Tanja Novakovic, Tatjana Ponorac, Mark Parker, Jurij Fürst, Dominic Tomek, Mercè Obach Cortadellas, Corrine Zara, Maria Juhasz-Haverinen, Peter Skiold, Stuart McTaggart, Alan Haycox

Research output: Contribution to journalArticlepeer-review

61 Downloads (Pure)


Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer
Original languageEnglish
Pages (from-to)49-70
Number of pages12
JournalGenerics and Biosimilars Initiative journal
Issue number2
Early online date2 Apr 2019
Publication statusPublished - 1 Jun 2019


  • cancer
  • pricing
  • generics
  • generic regulations
  • Europe
  • health policy
  • medicine pricing
  • pharmacy

Cite this